Bicycle Therapeutics plc(BCYC)

$4.38—

Chart

Bicycle Therapeutics plc(BCYC)

NASDAQ

$4.38—

Chart Studio

BCYC(BCYC)

BCYC

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.56

Aug 14, 2026 · Reports before open

Revenue Estimate

$5M

Analyst Sentiment

Wall St. Consensus

Buy

20 analysts·High coverage

Score

17 Buy (85%)3 Hold (15%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1785%

Hold

315%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$8.00

+82.6%

Consensus

$12.00

+174.0%

Bull

$12.00

+174.0%

12-Month Target Range20 analysts

$8.00$12.00$12.00

Current $4.38Consensus

Current Price

$4.38

Upside to Consensus

$7.62

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-31.38%

EPS—

FY2028

Rev+71.36%

EPS—

FY2029

Rev+67.60%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$23M	$16M	$27M	$46M	$169M
Low	$18M	$9M	$27M	$27M	$101M
High	$29M	$22M	$28M	$67M	$247M
EBITDA Avg	$-23M	$-16M	$-27M	$-46M	$-169M
Low	$-29M	$-22M	$-28M	$-67M	$-247M
High	$-18M	$-9M	$-27M	$-27M	$-101M
EBIT Avg	$-23M	$-16M	$-27M	$-46M	$-169M
Low	$-29M	$-22M	$-28M	$-67M	$-247M
High	$-18M	$-9M	$-27M	$-27M	$-101M
Net Income Avg	$-154M	$-162M	$-189M	$-113M	$-61M
Low	$-187M	$-199M	$-212M	$-181M	$-98M
High	$-103M	$-107M	$-89M	$-54M	$-29M
EPS Avg	$-2.26	$-2.33	$-2.17	$-1.64	$-0.88
Low	$-2.69	$-2.87	$-3.06	$-2.62	$-1.41
High	$-1.49	$-1.55	$-1.29	$-0.78	$-0.42
Analysts (Rev / EPS)	7 / 8	8 / 7	9 / 6	4 / 4	4 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$5M	$6M	$1M	$1M	$1M	$1M
Low	$3M	$4M	$809,687	$809,687	$809,687	$809,687
High	$6M	$8M	$2M	$2M	$2M	$2M
EBITDA Avg	$-5M	$-6M	$-1M	$-1M	$-1M	$-1M
Low	$-6M	$-8M	$-2M	$-2M	$-2M	$-2M
High	$-3M	$-4M	$-809,687	$-809,687	$-809,687	$-809,687
EBIT Avg	$-5M	$-6M	$-1M	$-1M	$-1M	$-1M
Low	$-6M	$-8M	$-2M	$-2M	$-2M	$-2M
High	$-3M	$-4M	$-809,687	$-809,687	$-809,687	$-809,687
Net Income Avg	$-34M	$-24M	$-38M	$-39M	$-41M	$-43M
Low	$-36M	$-37M	$-58M	$-60M	$-62M	$-65M
High	$-30M	$-15M	$-24M	$-25M	$-26M	$-27M
EPS Avg	$-0.48	$-0.35	$-0.55	$-0.57	$-0.59	$-0.62
Low	$-0.52	$-0.53	$-0.83	$-0.85	$-0.89	$-0.94
High	$-0.44	$-0.22	$-0.35	$-0.36	$-0.37	$-0.39
Analysts (Rev / EPS)	5 / 5	2 / 1	2 / 1	2 / 1	2 / 1	2 / 1

Earnings Surprises

Recent Analyst Actions

Apr 30, 2026Jefferies

Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies

Target:$12.00

+154.2%from $4.72

Apr 8, 2026Morgan Stanley

Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley

Target:$12.00

+141.0%from $4.98

Mar 17, 2026Truist Financial

Bicycle Therapeutics (BCYC) PT Lowered to $8 at Truist Securities

Target:$8.00

+57.2%from $5.09

Mar 17, 2026Morgan Stanley

Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right call'

Target:$13.00

+153.4%from $5.13

Nov 24, 2025Truist Financial

Bicycle Therapeutics initiated with a Hold at Truist

Target:$10.00

+58.2%from $6.32

Oct 31, 2025JMP Securities

Bicycle Therapeutics price target raised to $12 from $10 at Citizens JMP

Target:$12.00

+37.0%from $8.76

Oct 31, 2025RBC Capital

RBC downgrades Bicycle Therapeutics on slow pipeline progress

Target:$11.00

+25.6%from $8.76

Aug 11, 2025RBC Capital

Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital

Target:$27.00

+255.8%from $7.59

May 5, 2025Morgan Stanley

Bicycle Therapeutics price target raised to $17 from $15 at Morgan Stanley

Target:$17.00

+87.6%from $9.06

Dec 18, 2024JMP Securities

Bicycle Therapeutics price target lowered to $26 from $32 at JMP Securities

Target:$26.00

+69.7%from $15.32

Oct 24, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC)

Target:$48.00

+89.6%from $25.32

Oct 24, 2024B.Riley Financial

B.Riley Reiterates Neutral Rating on Bicycle Therapeutics (BCYC)

Target:$28.00

+10.6%from $25.32

Sep 16, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC)

Target:$55.00

+103.6%from $27.02

Oct 7, 2021Roth Capital

Bicycle Therapeutics (BCYC) PT Raised to $65 at Roth Capital

Target:$65.00

+33.5%from $48.69

Oct 7, 2021Piper Sandler

Bicycle Therapeutics price target raised to $76 from $46 at Piper Sandler

Target:$76.00

+56.1%from $48.69

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance